Procalcitonin (PCT) Biomarker: Diagnosis of Infectious Conditions

This report examines the diagnostic utility of Procalcitonin (PCT) in various infectious diseases. It highlights PCT's role in differentiating between aseptic inflammation and bacterial infections, particularly in early sepsis diagnosis. The report discusses PCT's advantages over conventional biomarke...Read More

Infectious Diseases
Introduction
Procalcitonin (PCT) is a significant diagnostic tool utilized for effectively diagnosing
the inflammatory conditions and associated clinical manifestations. The discrimination
between the pattern of aseptic inflammation and bacterial infection is made possible with the
utilization of PCT intervention (1). PCT approach is a newly invented modality that is
evidentially utilized for accurately diagnosing the early onset of severe sepsis and sepsis in
the patient population (2). PCT exhibits greater diagnostic specificity in terms of exploring a
range of infections that the conventional biomarkers fail to discover in the laboratory settings.
Although the blood culture intervention is the standard modality warranting utilization for
diagnosing the establishment of bacteremia and sepsis, PCT approach assists clinicians in
identifying the beginning stages of the infectious processes for taking calculated decisions in
the context of administering antimicrobial therapy (2). PCT intervention helps the treating
physicians in terms of undertaking calculated decisions regarding the dosage and length of
administration of antibiotic therapy for enhancing the treatment outcomes. Utilization of PCT
approach in diagnosing the early onset and establishment of non-infectious manifestations is
a subject of debate in the research community (2). The acquisition of an early diagnosis
(related to the infectious conditions) is made possible through the systematic utilization of
PCT modality and physical examination intervention with the objective of recommending
goal oriented antimicrobial approaches for the suspects of septic manifestations (2).
Evidence-based clinical literature affirms the adverse outcomes of the misutilization of
antibiotic therapy in terms of elevated mortalities among the burn patients affected with the
pattern of the initial shock (3). The inappropriate antimicrobial administration not only
elevates the healthcare costs of burn patients but also elevates the pattern of their microbial
resistance. Implementation of antimicrobial supervision with the systematic utilization of

PCT biomarker leads to the sustained reduction in the frequency of inappropriate antibiotic
prescription, its non-systematic administration and cessation in the hospital settings (3). PCT
modality proves advantageous in terms of the precise and timely tracking of the beginning of
systemic infection in predisposed patients (3). The clinical study by (3) affirms the reciprocal
alterations in the serum level of the PCT under the influence of the infectious progression.
Similarly, PCT levels decline in accordance with the decline in the systemic infectious
process under the influence of antimicrobial intervention. This signifies the role of PCT
modality in influencing the determination of dosage and time of the antimicrobial infection
for reducing the scope of occurrence of adverse events among the infected patients (3).
Normalization of PCT biomarker value sometimes indicates the development of
inflammatory processes (of non-infectious origin). Therefore, periodic assessment of the
serum PCT level in the infected patients is necessarily warranted for determining their
predisposition in terms of acquiring the pattern of non-inflammatory infectious processes
during the length of their stay in the clinical setting (3). Utilization of PCT modality appears
beneficial particularly in the late post-traumatic burn tenure that proves to be the preliminary
cause of mortalities among the burn patients. The patients experience substantial risk of
development of infectious processes during this tenure and therefore PCT intervention assists
clinicians in the context of deploying appropriate antibiotic interventions for systematically
enhancing the treatment outcomes (3). However, utilization of PCT modality in exploring the
extent of deterioration of regulatory pathways in severe burn cases remains questionable. The
potential of PCT intervention in effectively tracking the extent of cardiovascular and
hydroelectric disruptions caused under the influence of enhanced vascular permeability
emanating due to the release of systemic mediators in cases of burn injuries remains
questionable in the medical community (3). These clinical complications result in the
development of hypovolemia that becomes the leading cause of death of the burn patients.

Effectiveness of PCT modality requires further exploration in this context with the objective
of its systematic utilization in the burn settings (3). The research analysis by (4) confirms the
utilization of serum PCT in the context of tracking the onset, progression and establishment
of peritoneal infection in the setting of ascites and end-stage liver disease. The intensity of
peritoneal infection is determined by the extent of serum PCT elevation in the affected
patients (4). Evidence-based research literature indicates the elevation of serum PCT marker
in cases of fungal manifestations of intra-abdominal origin (5). Utilization of PCT
intervention is substantiated in cases of necrotizing pancreatitis as well as post-operative
(intra-abdominal) infections (5). However, the detailed analysis of PCT pathways in intra-
abdominal infection settings in the need of today and warrants effective undertaking by the
research community. In my own ward, the physicians recommend the utilization of PCT
modality in diagnosing the pattern of lower respiratory tract infections. In many clinical
scenarios, the administration of PCT biomarker utility helps in identifying the early onset and
progression of acute lower respiratory tract infections of respiratory origin. However, PCT
modality is not prevalently utilized in tracking the pattern of bacterial progression in cases of
upper respiratory tract infections. Evidence-based research literature advocates the
requirement of elevating the sensitivity of PCT modality with the objective of monitoring the
extent of bacterial invasion in patients affected with infectious respiratory tract
manifestations (6). The pattern of lower respiratory tract infection (LRTI) includes the
diseases like pneumonia, asthma, chronic obstructive pulmonary disease (COPD) (acute
exacerbation) as well as acute bronchitis (6). Physicians configure antibiotic interventions in
accordance with the recorded levels of PCT biomarker in LRTI cases (6). The standard
diagnostic modality utilized in my clinical setting for diagnosing the pattern of lower and
upper urinary tract infections attributes to the CRP (C-reactive protein) intervention. The
clinical findings by (7) also indicate the diagnostic potential of CRP modality in terms of

differentiating the pattern of lower and upper urinary tract infections. However, the PCT
modality proves more specific and sensitive in terms of diagnosing the onset of
pyelonephritis in comparison to the CRP intervention (8). Therefore, PCT biomarker is the
modality of choice warranted for tracking the progression of bacterial invasion in lower and
upper urinary tract infections associated with renal involvement (8). The research
investigation by (9) indicates the significance of PCT biomarker in terms of increasing the
precision of diagnosing the onset of various infectious processes affecting the lungs, heart,
abdomen and blood of the patient population.
Summary of the Article
The systematic analysis by (9) evidentially investigates the potential of PCT
biomarker intervention in terms of enhancing the diagnostic accuracy in patients affected
with the pattern of bacterial infections and associated symptomatology. The outcomes of this
diagnostic intervention positively influence the clinicians’ decisions regarding the extent and
duration of administration of antimicrobial therapy to the population of interest (9). The
entire research intervention revolves around the systematic diagnostic assessment of sepsis
and lower respiratory tract infectious processes. The study findings reveal the high efficacy of
PCT modality in precisely diagnosing infectious conditions attributing to acute heart failure,
meningitis, postoperative bacterial infections and urinary tract and respiratory tract infections
(9). PCT biomarker modality exhibits high potential in terms of reducing unnecessary
utilization of antimicrobial treatment for treating low-risk conditions across the inpatient
setting. These low-risk conditions could include the pattern of COPD exacerbation and
bronchitis (9). The regular assessment of PCT pathways and kinetics in the hospital setting
lead to the considerable reduction in the antibiotic administration duration, as revealed by the
study findings (9). In many clinical scenarios, (as identified by the study intervention)
physicians effectively ceased antimicrobial intervention in accordance with the analysis of

the PCT findings (9). The study findings consider PCT biomarker modality as the safest
diagnostic intervention that substantially reduces the risk of treatment failures, infection
relapse and associated mortalities in patients affected with various contagious conditions (9).
The systematic analysis of the serum PCT levels in various disease conditions assists in
evidently determining the prognosis of various disease conditions attributing to sepsis,
abdominal infection and pancreatitis (9). The non-application of PCT modality in various
non-infectious as well as chronic disease conditions makes it a subject of further investigation
by the research community. The suboptimal specificity and sensitivity of PCT biomarker
intervention in selected disease processes warrants the requirement of careful monitoring of
serum PCT levels for retaining the precision level of the diagnostic outcomes (9). The
systematic analysis evaluated various study designs including RCT and observational
interventions and explored the effectiveness of PCT modality in undertaking safe discharge
management of patients after the administration of surgical interventions. The study
outcomes confirmed the reduction in the length of antimicrobial intervention in cases of
pulmonary fibrosis, community-acquired pneumonia, bronchitis, asthma, AECOPD and
upper respiratory tract infections (9). The study findings also revealed the capacity of PCT
modality in terms of identifying the pattern of bacterial superinfection in patients affected
with congestive heart failure (9). PCT biomarker modality proves effective in terms of
predicting the adverse prognostic outcomes bacterial endocarditis and associated clinical
manifestations (9). PCT-guided intervention evidently reduces the length of exposure to
antibiotic therapy in patients affected with the disease conditions like a urinary tract infection,
pancreatitis, peritonitis and abdominal infections (9). PCT modality exhibits high diagnostic
value in cases of appendicitis associated with adverse clinical complications. This
intervention evidentially reduces the length of antibiotic intervention as well as associated
moralities in patients affected with the pattern of septic shock and severe sepsis (9). The

sustained reduction in the PCT level in the peri-operative period affirms the absence of
infectious processes and facilitates the timely discharge of the treated patient (9). PCT
modality proves beneficial in diagnosing the pattern of infection in the setting of rheumatoid
arthritis. Serum PCT levels evidentially identify the onset and progression of deep venous
thrombosis and erysipelas in the hospital setting (9). Analysis of CSF lactate and serum PCT
levels assists in tracking the development of bacterial meningitis that reciprocally reduces the
duration of antibiotic administration in the affected patients (9).
Critical Analysis of the Article
The greatest limitation of the research intervention by (9) relates to the fact that the
authors did not undertake an in-depth review and analysis of each of the discussed disease
types in the context of determining their diagnostic analysis with the sole utilization of PCT
biomarker utility. The research analysis by briefly discussed regarding the reduction in the
duration of antibiotic therapy as well as antibiotic exposure with the utilization of PCT
intervention. However, the study failed to undertake statistical analysis for comparing the rate
of antibiotic prescription and the relative predisposition of antibiotic exposure in the clinical
setting of asthma. The study also did not analyse the pulmonary functionality of the asthmatic
patients after undergoing reduction in the duration of antibiotic therapy in accordance with
the PCT analysis. Therefore, the PCT findings in relation to the asthmatic diagnostic
assessment (undertaken with the objective of acquiring the goal oriented therapeutic
outcomes) appear questionable that warrants their further investigation through prospective
research studies. This requirement is also revealed by the evidence-based analysis that
affirms the requirement of establishing secondary end-points for exploring the pulmonary
functionality of the asthmatic patients as well as their serum PCT levels (during the follow-up
period) after the complete cessation of antibiotic therapy (10). Another limitation of the
research analysis by (9) relates to the lack of comparative analysis of PCT modality with

other similar interventions on a wider scale. A limited comparison of PCT intervention with
CRP modality in UTI cases might not suffice the requirement of utilizing PCT biomarker
approaches in precisely diagnosing the initial stages of various infectious processes as well as
contagious conditions. The comparative assessment of CRP with markers including IL-8, IL-
6, CRP and cytokines is necessarily required for understanding it’s true diagnostic potential
for various infectious and non-infectious disease conditions (11). The researchers also need to
investigate the influence of external factors on the serum levels of various biomarkers for
objectively reducing the probability of existence of confounding factors and associated bias
in the diagnostic accuracy. For example, the CRP level considerably elevates under the
influence of trauma that might not affirm the existence of urinary tract infection (12).
Similarly, PCT level could substantially elevate immediately after the administration of
surgical intervention (13). The researchers need to explore the extent of these elevations
under the influence of external circumstances in the context of including or excluding the
respective biomarker modalities while undertaking the diagnostic analysis of the diseased
patient. For example, the serum level of IL-6 biomarker might elevate beyond 1000 pg/mL in
cases of severe systemic inflammation and intra-amniotic infection (14). Similarly, lactate
levels could elevate above 4 mmol/L in cases of organ dysfunction associated with severe
sepsis. The serum CRP level might elevate beyond 50 mg/mL following the administration of
major and minor surgical interventions and 11 mg/L in the setting of rheumatoid arthritis
(15). These evidence-based findings substantially indicate the requirement of conducting
prospective systematic studies as well as RCT and observational interventions for configuring
predefined benchmarks regarding the optimal and suboptimal concentration of the PCT in
relation to various disease outcomes. This will evidently improve the evidence-based
utilization of PCT intervention and improve the diagnostic accuracy of this modality for the
systematic acquisition of the therapeutic benefits. Contrarily, the greatest strength of the

research analysis by (9) attributes to the fact that it systematically evaluated a range of
randomized controlled interventions and observational studies for affirming the diagnostic
accuracy of PCT modality in the context of improving the therapeutic management of various
infectious conditions and their associated adverse manifestations.
Conclusion
The evidence-based analysis of the findings by (9) indicates the requirement of
conducting prospective double blinded randomized controlled interventions with the
objective of determining the diagnostic potential of PCT biomarker approach in tracking the
onset of various infectious as well as inflammatory disease conditions. The study findings
also substantiate the requirement of analysing the application of PCT intervention on a wider-
scale with the objective of tracking the establishment of chronic and well as non-infectious
disease conditions across the community environment. Indeed, prospective enhancement in
the precision (i.e. specificity and sensitivity) of PCT biomarker modality will eventually
improve the associated antibiotic stewardship in various clinical settings.
References
x
1. Maus U, Andereya S, Gravius S, Ohnsorge JA, Miltner O, Niedhart C. Procalcitonin

(PCT) as diagnostic tool for the monitoring of spondylodiscitis. Zeitschrift für
Orthopädie und Unfallchirurgie. 2009; 147(1): p. 59-64.
2. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of
sepsis. Diagnostic Microbiology and Infectious Disease. 2012; 73(3): p. 221-227.
3. Cabral L, Afreixo V, Almeida L, Paiva JA. The Use of Procalcitonin (PCT) for
Diagnosis of Sepsis in Burn Patients: A Meta-Analysis. PLoS One. 2016; 11(12).
4. Wu J, Jiang F, Zeng T, Xu H, Lei Y, Zhong S, et al. Role of serum procalcitonin assay
for diagnosis of spontaneous bacterial peritonitis in end-stage liver diseases. Zhongguo
Yi Xue Ke Xue Yuan Xue Bao. 2014; 36(1): p. 37-41.
5. Watkins RR, Lemonovich TL. Serum procalcitonin in the diagnosis and management of
intra-abdominal infections. Expert Review of Anti-Infective Therapy. 2012; 10(2): p.
197-205.
6. Wróblewski T, Marcisz C. Procalcitonin as a biomarker of acute lower respiratory tract
infections. Expert Opinion on Medical Diagnostics. 2009; 3(1): p. 67-69.
7. Agrawal P, Pandey A, Sompura S, Pursnani ML. Role of blood C - reactive protein levels
in upper urinary tract infection and lower urinary tract infection in adult patients (>16
years). The Journal of the Association of Physicians of India. 2013; 61(7): p. 462-463.
8. Xu RY, Liu HW, Liu JL, Dong JH. Procalcitonin and C-reactive protein in urinary tract
infection diagnosis. BMC Urology. 2014.
9. Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic
stewardship revisited. BMC Medicine. 2017.
10. Tang J, Long W, Yan L, Zhang Y, Xie J, Lu G, et al. Procalcitonin guided antibiotic
therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious

Diseases. 2013.
11. Meisner M. Update on Procalcitonin Measurements. Annals of Laboratory Medicine.
2014; 34(4): p. 263–273.
12. NCBI. CRP C-reactive protein [ Homo sapiens (human) ]. USA: NCBI; 2017. Report
No.: Gene ID: 1401.
13. Sakran JV, Michetti CP, Sheridan MJ, Richmond R, Waked T, Aldaghlas T, et al. The
utility of procalcitonin in critically ill trauma patients. The Journal of Trauma and Acute
Care Surgery. 2012; 73(2): p. 413-418.
14. Chaemsaithong P, Romero R, Docheva N, Chaiyasit N, Bhatti G, Pacora P, et al.
Comparison of rapid MMP-8 and interleukin-6 point-of-care tests to identify intra-
amniotic inflammation/infection and impending preterm delivery in patients with preterm
labor and intact membranes. The Journal of Maternal-Fetal and Neonatal Medicine.
2017;: p. 1-17.
15. Graf J, Scherzer R, Grunfeld C, Imboden J. Levels of C-Reactive Protein Associated with
High and Very High Cardiovascular Risk Are Prevalent in Patients with Rheumatoid
Arthritis. PLoS One. 2009; 4(7).
x